JP2003523313A - シャペロン蛋白質の阻害方法 - Google Patents

シャペロン蛋白質の阻害方法

Info

Publication number
JP2003523313A
JP2003523313A JP2000603658A JP2000603658A JP2003523313A JP 2003523313 A JP2003523313 A JP 2003523313A JP 2000603658 A JP2000603658 A JP 2000603658A JP 2000603658 A JP2000603658 A JP 2000603658A JP 2003523313 A JP2003523313 A JP 2003523313A
Authority
JP
Japan
Prior art keywords
protein
client
coumarin
polypeptide
chaperone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000603658A
Other languages
English (en)
Japanese (ja)
Inventor
ジー． マルスュ、モニカ
エム． ネッカーズ、レオナルド
ダヴリュ． シュルト、テオドール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Government
Original Assignee
US Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Government filed Critical US Government
Publication of JP2003523313A publication Critical patent/JP2003523313A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2000603658A 1999-03-12 2000-03-10 シャペロン蛋白質の阻害方法 Pending JP2003523313A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12413599P 1999-03-12 1999-03-12
US60/124,135 1999-03-12
PCT/US2000/006482 WO2000053169A2 (en) 1999-03-12 2000-03-10 Method of inhibiting a chaperone protein

Publications (1)

Publication Number Publication Date
JP2003523313A true JP2003523313A (ja) 2003-08-05

Family

ID=22412989

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000603658A Pending JP2003523313A (ja) 1999-03-12 2000-03-10 シャペロン蛋白質の阻害方法

Country Status (5)

Country Link
EP (1) EP1161231A2 (de)
JP (1) JP2003523313A (de)
AU (1) AU776652B2 (de)
CA (1) CA2367108A1 (de)
WO (1) WO2000053169A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010055929A1 (ja) * 2008-11-14 2010-05-20 国立大学法人京都大学 Ｈｓｐ９０を標的にした新規抗がんキメラペプチド

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858331B2 (en) 2000-11-03 2010-12-28 Dana Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
EP1387678A1 (de) * 2001-05-03 2004-02-11 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Verbindungen,die hsp90 stimulieren und hsp70 und hsp40 inhibieren, und deren verwendung zur prophylaxis und behandlung von krankheiten, die mit protein aggregation und mit amyloid bildung verbunden sind
EP1457499A1 (de) * 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitoren des extrazellulären Hitzeschockproteins Hsp90
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
CN100567242C (zh) 2003-06-27 2009-12-09 协和发酵麒麟株式会社 Hsp90家族蛋白质阻断剂
DE102004039280A1 (de) 2004-08-13 2006-02-23 Merck Patent Gmbh 1,5-Diphenyl-pyrazole
DE102004049078A1 (de) 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
WO2006050501A2 (en) * 2004-11-03 2006-05-11 University Of Kansas Novobiocin analogues as anticancer agents
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
DE102005009440A1 (de) 2005-03-02 2006-09-07 Merck Patent Gmbh Thienopyridinderivate
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
DE102007032739A1 (de) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
DE102007041116A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh 1,3-Dihydro-isoindolderivate
DE102008061214A1 (de) 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate
CN101942017B (zh) 2009-07-07 2013-08-14 清华大学 一种新的肿瘤标志物
DE102009054302A1 (de) 2009-11-23 2011-05-26 Merck Patent Gmbh Chinazolinderivate
DE102010046837A1 (de) 2010-09-29 2012-03-29 Merck Patent Gmbh Phenylchinazolinderivate
WO2012162054A1 (en) * 2011-05-20 2012-11-29 The University Of Kansas Dynamic inhibitors of heat shock protein 90

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216014A (en) * 1991-09-10 1993-06-01 Sphinx Pharmaceuticals Corporation Furo-coumarinsulfonamides as protein kinase C inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6010065598, Ｎｏｒｄｅｎｂｅｒｇ， Ｊ．， ｅｔ ａｌ．, ""Ｎｏｖｏｂｉｏｃｉｎ−ｉｎｄｕｃｅｄ ａｎｔｉ−ｐｒｏｌｉｆｅｒａｔｉｖｅ ａｎｄ ｄｉｆｆｅｎｒｅｎｔｉａｔｉｎｇ ｅｆｆｅｃｔｓ ｉｎ ｍｅｌａｎｏｍａ Ｂ１６"", Ｂｒｉｔｉｓｈ Ｊｏｕｒｎａｌ ｏｆ Ｃａｎｃｅｒ, 1992, ｖｏｌ．６５， ｎｏ．２, ｐｐ．１８３−１８８ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010055929A1 (ja) * 2008-11-14 2010-05-20 国立大学法人京都大学 Ｈｓｐ９０を標的にした新規抗がんキメラペプチド
US8546320B2 (en) 2008-11-14 2013-10-01 Kyoto University Hsp9O-targeted anti-cancer chimeric peptide

Also Published As

Publication number Publication date
AU3740600A (en) 2000-09-28
WO2000053169A2 (en) 2000-09-14
CA2367108A1 (en) 2000-09-14
EP1161231A2 (de) 2001-12-12
AU776652B2 (en) 2004-09-16
WO2000053169A8 (en) 2001-01-11

Similar Documents

Publication Publication Date Title
JP2003523313A (ja) シャペロン蛋白質の阻害方法
US20230123747A1 (en) Selective grp94 inhibitors and uses thereof
Chiosis et al. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells
Grem et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors
Henry et al. Flavone antagonists bind competitively with 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) to the aryl hydrocarbon receptor but inhibit nuclear uptake and transformation
KR20030071767A (ko) 에이치에스피90에 결합하기 위한 소분자 조성물
KR20010089154A (ko) 아데노신 에이3 수용체 조절제
US9114126B2 (en) Na/K-ATPase ligands, ouabain antagonists, assays and uses thereof
Derkach et al. In vitro and in vivo studies of functional activity of new low molecular weight agonists of the luteinizing hormone receptor
Zhang et al. Triptolide, a HSP90 middle domain inhibitor, induces apoptosis in triple manner
Deng et al. Dehydrocurvularin is a potent antineoplastic agent irreversibly blocking ATP-citrate lyase: evidence from chemoproteomics
Abbruzzese et al. The small molecule SI113 hinders epithelial‐to‐mesenchymal transition and subverts cytoskeletal organization in human cancer cells
Zhong et al. Discovery of deoxyvasicinone derivatives as inhibitors of NEDD8-activating enzyme
Derkach et al. New Thieno-[2, 3-d] pyrimidine-based functional antagonist for the receptor of thyroid stimulating hormone
WO2021005183A1 (en) Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations
Kim et al. A gonadotropin-releasing hormone-II antagonist induces autophagy of prostate cancer cells
Maeng et al. Addition of amino acid moieties to lapatinib increases the anti‐cancer effect via amino acid transporters
Sun et al. Design, synthesis and pharmacological evaluation of 2-arylurea-1, 3, 5-triazine derivative (XIN-9): a novel potent dual PI3K/mTOR inhibitor for cancer therapy
Yu et al. Evodiamine as a novel antagonist of aryl hydrocarbon receptor
Hong et al. A small molecule pan-inhibitor of Ras-superfamily GTPases with high efficacy towards Rab7
Culty et al. Peripheral benzodiazepine receptor binding properties and effects on steroid synthesis of two new phenoxyphenyl‐acetamide derivatives, DAA1097 and DAA1106
Lei et al. Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments
WO2023023376A2 (en) Sulfonyl-triazoles useful as covalent kinase ligands
Derkach et al. Low-Molecular-Weight Ligands of Luteinizing Hormone Receptor with the Activity of Antagonists
Kiesel et al. Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110419